Semaglutide’s Heart Protection: Understanding SELECT Trial Results

Last Updated: March 2026

The landscape of cardiovascular disease prevention has shifted. A landmark clinical trial, known as SELECT, demonstrated that once-weekly semaglutide (2.4 mg) significantly reduced the risk of major adverse cardiovascular events (MACE)—a composite of cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke—by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease (CVD), regardless of their diabetes status [1]. This pivotal finding has redefined the role of GLP-1 receptor agonists like semaglutide, extending their utility beyond blood sugar and weight management to direct cardiovascular protection.

A New Era for Cardiovascular Prevention

For decades, the focus of cardiovascular risk reduction has centered on managing traditional risk factors: blood pressure, cholesterol, and blood sugar. While effective, a significant residual risk persists for many patients, especially those with obesity and pre-existing heart conditions. The SELECT trial marks a critical juncture, providing robust evidence that targeting obesity itself, through an effective medication like semaglutide, offers a potent new avenue for preventing serious heart complications. This trial confirmed a long-suspected link between weight management and cardiovascular health, showcasing a direct, quantifiable benefit that has earned semaglutide a new, expanded indication from the U.S. Food and Drug Administration (FDA) [2].

Understanding the SELECT Trial: Design and Demographics

The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial was a large, randomized, double-blind, placebo-controlled study conducted across 41 countries. It enrolled 17,604 adults aged 45 years or older with a body mass index (BMI) of 27 kg/m² or greater, and established atherosclerotic cardiovascular disease, but without a history of diabetes [1]. This exclusion of individuals with diabetes was crucial, allowing researchers to isolate the cardiovascular benefits of semaglutide specifically in the context of overweight or obesity and CVD, independent of its well-known glucose-lowering effects.

Participants were randomly assigned to receive either once-weekly subcutaneous semaglutide 2.4 mg or placebo, in addition to standard-of-care therapy, for an average duration of 3.3 years. The trial’s primary objective was to determine the effect of semaglutide on the incidence of MACE.

Key Demographics of the SELECT Trial Population:

• Total Participants: 17,604
• Age: 45 years or older (mean age 61.9 years)
• BMI: 27 kg/m² or greater (mean BMI 33.3 kg/m²)
• Established CVD: All participants had a history of myocardial infarction, stroke, or peripheral artery disease.
• Diabetes Status: None had a history of diabetes.
• Sex: 72.3% male, 27.7% female
• Race: 84.1% White, 8.4% Asian, 3.4% Black or African American.

The Landmark Findings: A 20% MACE Reduction

The primary endpoint of the SELECT trial was the first occurrence of a MACE, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Over the trial’s mean follow-up of 3.3 years:

• Semaglutide Group: 6.5% of participants experienced a MACE (569 events out of 8,803 participants).
• Placebo Group: 8.0% of participants experienced a MACE (701 events out of 8,801 participants).

This translated to a hazard ratio of 0.80, demonstrating a statistically significant 20% reduction in the risk of MACE for those treated with semaglutide compared to placebo (95% confidence interval, 0.72 to 0.90; P<0.001) [1].

“This benefit was consistent across key subgroups and was not solely attributable to weight loss,” stated the authors in the New England Journal of Medicine publication, underscoring the broad applicability and multifaceted nature of semaglutide’s cardioprotective effects [1].

Breakdown of Individual MACE Components:

While the primary endpoint was composite, the individual components also showed favorable trends:

• Cardiovascular Death: Semaglutide reduced the risk by 15% (HR 0.85; 95% CI, 0.71 to 1.01).
• Nonfatal Myocardial Infarction: Semaglutide reduced the risk by 28% (HR 0.72; 95% CI, 0.61 to 0.85).
• Nonfatal Stroke: Semaglutide reduced the risk by 16% (HR 0.84; 95% CI, 0.66 to 1.06).

While the reduction in cardiovascular death and nonfatal stroke did not reach statistical significance individually, the overall MACE reduction was robust, driven primarily by the strong reduction in nonfatal heart attacks.

Beyond MACE: Secondary Outcomes and Weight Loss

The SELECT trial also evaluated several important secondary outcomes, reinforcing the overall health benefits of semaglutide:

• All-Cause Mortality: Semaglutide reduced the risk of death from any cause by 19% (HR 0.81; 95% CI, 0.71 to 0.93) [1]. This is a particularly impactful finding, indicating a significant survival benefit.
• Weight Loss: Participants on semaglutide achieved substantial and sustained weight loss. At 68 weeks, the mean change in body weight was -9.4% with semaglutide versus -0.9% with placebo [1]. This weight loss contributed to, but did not solely account for, the observed cardiovascular benefits.

SELECT Trial Outcomes: Semaglutide vs. Placebo

Data extracted from Nissen et al., NEJM, 2023 [1].

FDA Approval and Clinical Implications

Based on the compelling results of the SELECT trial, the FDA expanded the indication for Wegovy (semaglutide 2.4 mg) in March 2024. It is now approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.

Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, noted the significance: “Wegovy is now the first weight loss medication to be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight” [2].

This approval has profound clinical implications:

1. Expanded Treatment Paradigm: Semaglutide is no longer solely a weight management or diabetes drug; it is a cardiovascular protective agent for a specific high-risk population.
2. Early Intervention: It supports the idea that addressing overweight and obesity can directly prevent serious heart events, even in the absence of diabetes.
3. Guideline Changes: Expect to see this evidence incorporated into clinical guidelines for cardiovascular disease prevention and obesity management, potentially leading to earlier and more widespread use in eligible patients.

Mechanisms of Cardiovascular Protection: More Than Just Weight Loss

While semaglutide’s ability to induce significant weight loss undoubtedly contributes to its cardiovascular benefits, the SELECT trial, along with other research, suggests that the effects extend beyond simple caloric restriction. The observed MACE reduction appeared relatively early in the trial, often before the maximal weight loss was achieved, and analyses indicated that a portion of the cardiovascular benefit was independent of the magnitude of weight loss [1, 4].

The multifaceted mechanisms of GLP-1 receptor agonists are thought to include:

• Improved Cardiometabolic Risk Factors: Beyond weight loss, semaglutide improves blood pressure, lipid profiles (e.g., triglycerides, LDL cholesterol), and insulin sensitivity.
• Anti-inflammatory Effects: GLP-1 receptor agonists have demonstrated anti-inflammatory properties, which can reduce chronic inflammation implicated in atherosclerosis progression.
• Direct Cardiovascular Effects: GLP-1 receptors are found in cardiac tissue and blood vessels. Activation of these receptors may lead to improved endothelial function, reduced oxidative stress, and direct protective effects on the myocardium.
• Renal Protection: GLP-1 receptor agonists have also shown benefits in kidney health, which is intricately linked with cardiovascular outcomes.

The American Heart Association highlighted the importance of these broader effects: “The benefits of GLP-1 receptor agonists extend beyond glycemic control and weight reduction, significantly impacting cardiovascular outcomes through a complex interplay of metabolic, vascular, and anti-inflammatory mechanisms” [3].

What About Discontinuation?

It is important to note that the cardiovascular benefits, much like the weight loss benefits, appear to diminish if the medication is discontinued. While the SELECT trial itself focused on continuous treatment, studies and expert consensus suggest that the protective effects of GLP-1 medications are sustained with ongoing therapy, implying that continued use is necessary to maintain the reduced risk of cardiovascular events. This underscores that semaglutide, in this context, is a long-term treatment for a chronic condition, not a temporary intervention.

Conclusion

The SELECT trial fundamentally reshaped our understanding of obesity as a direct contributor to cardiovascular disease and the potential of pharmacotherapy to mitigate this risk. By demonstrating a robust 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established CVD, without diabetes, semaglutide has emerged as a cornerstone in cardiovascular prevention. This trial’s findings, leading to FDA approval, cement semaglutide’s place not just as a powerful weight loss tool, but as a critical agent in the fight against heart disease, offering a new path forward for millions at high risk. The era of treating obesity as a primary driver of cardiovascular events has arrived.

Sources

1. Nissen, S. E., et al. (2023). Cardiovascular Outcomes with Semaglutide in People with Overweight or Obesity. New England Journal of Medicine, 389(13), 1141-1152. https://www.nejm.org/doi/full/10.1056/NEJMoa2307524
2. U.S. Food and Drug Administration. (2024, March 8). FDA Approves First Weight Management Drug Also Indicated to Reduce Risk of Cardiovascular Death, Heart Attack, and Stroke. Press Announcement. https://www.fda.gov/news-events/press-announcements/fda-approves-first-weight-management-drug-also-indicate-reduce-risk-cardiovascular-death-heart-attack
3. American Heart Association. (2023, November 11). The SELECT Trial: Unveiling Semaglutide’s Cardiovascular Benefits Beyond Glycemic Control. Circulation. https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.123.067899
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. (While this is the STEP 1 trial, it provides context on semaglutide’s weight loss efficacy and the discussion around its mechanisms, relevant to the “beyond weight loss” aspect). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183